Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials
Executive Summary
While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop